

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: Titilola Afolabi (Wolters Kluwer); Danielle Lazear (Wolters Kluwer); David E. Procaccini (American Heart Association, Council on Clinical Cardiology Pharmacology Committee); Christopher A. Thomas (Wolters-Kluwer); Susan Villegas (National Association of Boards of Pharmacy); Regine White (American Society of Health-System Pharmacists)

Stock Ownership:

Royalties: David E. Procaccini (Silvergate Pharmaceuticals)

Grants: Christa Jefferis Kirk (AltaThera Pharmaceuticals); Danielle Lazear (Cincinnati Children's Hospital, Center for Pediatric Genomics); Jessica Otero (AltaThera Pharmaceuticals); David E. Procaccini (Grifols Pharmaceutical Co.); Christopher A. Thomas (Phoenix Children's Hospital)

Honoraria: Jessica Otero (American Society of Health-System Pharmacists); David E. Procaccini (Pediatric Pharmacy Advocacy Group)

Other: Tara L. Smith (provides review services for ASHP board certification materials)

Nothing to disclose: Amanda Baker; Meghan Baldo; Brian K. Brown; Esther C. Chu; Jennifer Gilarde; Elizabeth Goswami; Richard J. Haftmann; Brent Hall; Jennifer Hewlett; Alyssa Hobby; Tim Humlicek; Amy Kiskaddon; Dominique G. Mark; Brady Moffett; Jennifer Pak; Eric R. Pfeifer; Julie Pingel; E. Zachary Ramsey; Michael Raschka; Gale L. Romanowski

ROLE OF BPS: The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. PedSAP has been approved by BPS for use in BCPPS recertification. Information about the BPS recertification process is available [online](#).

Questions regarding BCPPS recertification should be directed to:

[Board of Pharmacy Specialties](#)
2215 Constitution Avenue NW
Washington, DC 20037
(202) 429-7591